Clinical Trials
178
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (168 trials with phase data)• Click on a phase to view related trials
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
- Conditions
- Colon CancerRectal CancerColorectal CancerColorectal Cancer (CRC)
- Interventions
- Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
- First Posted Date
- 2025-06-09
- Last Posted Date
- 2025-11-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT07011576
- Locations
- 🇺🇸
Virginia Oncology Associates, Norfolk, Virginia, United States
🇺🇸Rocky Mountain Cancer Center - Primary, Denver, Colorado, United States
🇺🇸Maryland Oncology Hematology, Columbia, Maryland, United States
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- Conditions
- Multiple Myeloma, Newly DiagnosedMultiple Myeloma (MM)
- Interventions
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-11-06
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT06974786
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
🇺🇸University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
- Conditions
- Limited Stage Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-01-14
- Last Posted Date
- 2025-11-06
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 250
- Registration Number
- NCT06773910
- Locations
- 🇺🇸
Missouri Cancer Associates, Columbia, Missouri, United States
🇺🇸White Plains Hospital Physician Associates, White Plains, New York, United States
🇺🇸Texas Oncology- Austin, Austin, Texas, United States
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2025-10-29
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 75
- Registration Number
- NCT05972135
- Locations
- 🇺🇸
Vanderbilt- Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Arizona Oncology Associates, Tucson, Arizona, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib
- Conditions
- Non-small Cell Lung CancerLung Cancer
- Interventions
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- SCRI Development Innovations, LLC
- Registration Number
- NCT05948462
- Locations
- 🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸Messino Cancer Center, Asheville, North Carolina, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 36
- Next